LOLA is therefore able to reduce HE by inducing nitrogen metabolism to decrease blood and CSF ammonia levels.[7] Lastly, studies have also demonstrated that albumin infusion may reduce occurrence of overt HE in patients with cirrhosis, as albumin has an established role in plasma expansion and decreases risks of cirrhosis-related complications related to circulatory dysfunction.[8] Currently, the European association for the study of the liver (EASL) (2022) recommends that patients with covert HE be treated with nonabsorbable disaccharides. This evidence concerns the gene ALB and hereditary elliptocytosis.